enow.com Web Search

  1. Ad

    related to: pertuzumab and trastuzumab neoadjuvant therapy for complex injection

Search results

  1. Results from the WOW.Com Content Network
  2. Pertuzumab - Wikipedia

    en.wikipedia.org/wiki/Pertuzumab

    Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

  3. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

    The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...

  4. Breast cancer management - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer_management

    Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.

  5. Trastuzumab - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab

    Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [31] [28] [32] [33] It is specifically used for cancer that is HER2 receptor positive. [31]

  6. Trastuzumab emtansine - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_emtansine

    In the United States, trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy ...

  7. Trastuzumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab/hyaluronidase

    Clinical trial number NCT01566721 for "A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)" at ClinicalTrials.gov

  8. Trastuzumab deruxtecan - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_deruxtecan

    Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...

  9. Tucatinib - Wikipedia

    en.wikipedia.org/wiki/Tucatinib

    Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

  1. Ad

    related to: pertuzumab and trastuzumab neoadjuvant therapy for complex injection